Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult
Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity London, UK – September 23, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader…...
Read MoreQuell Therapeutics to Present at the 2021 Wedbush Pacgrow Healthcare Virtual Conference
London, UK and Boston, MA, USA, August 4, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that Iain McGill, Chief Executive…...
Read MoreQuell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer
Dr. Hartl, former Therapeutic Area Head – Autoimmunity/Transplantation/Inflammation at Novartis Institutes for Biomedical Research (NIBR), to lead Quell's innovative multi-modular Treg cell therapy programs into clinical development LONDON and BOSTON, July 29, 2021 - Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered…...
Read MoreQuell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer
Dr. Hartl, former Therapeutic Area Head – Autoimmunity/Transplantation/Inflammation at Novartis Institutes for Biomedical Research (NIBR), to lead Quell's innovative multi-modular Treg cell therapy programs into clinical development LONDON, July 22, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered…...
Read MoreBioCentury – Quell: tweaking Tregs for persistence, potency and stability
London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability. To view the full article please click here...
Read MoreQuell Therapeutics Expands Series A Financing to $84 Million
– Largest Series A in the Treg field – – Lead program is a first-in-class treatment targeting liver transplantation with engineered Treg cell therapy – – First program expected to enter the clinic in first half of 2022 – London,…...
Read MoreQuell Therapeutics Enters a Collaborative Research Agreement with the University of Sheffield
Collaboration will accelerate Quell’s pipeline expansion into neuroinflammatory diseases London and Sheffield, UK – October 26, 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative…...
Read MoreQuell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir Robert Lechler and hires Dr Natalie Belmonte as SVP Research & Translation
London – June 11 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the appointments of seasoned industry expert, Dr Dhaval Patel, Executive Vice President and Chief Scientific Officer UCB S.A. (Brussels, Belgium),…...
Read MoreQuell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School
Collaboration will accelerate Quell’s pipeline expansion into autoimmune and inflammatory diseases London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a…...
Read More